Drug Description in Trials / DrugBank / KEGG DRUG


Search results


No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1Dupilumab[1] Dupilumab (Dupilumab)[1] Dupilumab (Dupilumab) 💬 [1] IL4R 💬 [8] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬[8] 51, 97, 98, 160, 162, 222, 300, 306 💬
2Dupilumab (blinded)[1] Dupilumab (Dupilumab)[1] Dupilumab (Dupilumab) 💬 [1] IL4R 💬 [8] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬[1] 98 💬
3Dupilumab (open-label)[1] Dupilumab (Dupilumab)[1] Dupilumab (Dupilumab) 💬 [1] IL4R 💬 [8] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬[1] 98 💬
4Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT][1] Dupilumab (Dupilumab)[1] Dupilumab (Dupilumab) 💬 [1] IL4R 💬 [8] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬[1] 98 💬
5Dupilumab 300Mg Solution for Injection[1] Dupilumab (Dupilumab)[1] Dupilumab (Dupilumab) 💬 [1] IL4R 💬 [8] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬[1] 51 💬
6Dupilumab Injection[1] Dupilumab (Dupilumab)[1] Dupilumab (Dupilumab) 💬 [1] IL4R 💬 [8] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬[1] 160 💬
7Dupilumab open label extension phase[1] Dupilumab (Dupilumab)[1] Dupilumab (Dupilumab) 💬 [1] IL4R 💬 [8] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬[1] 222 💬
8Dupilumab Prefilled Syringe[1] Dupilumab (Dupilumab)[1] Dupilumab (Dupilumab) 💬 [1] IL4R 💬 [8] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬[1] 160 💬
9Secukinumab was administered in a weight-adapted dosing regimen ? Dupilumab was administered at a dose dependent on the patient's weight and age[2] Dupilumab (Dupilumab),
Secukinumab
[2] Secukinumab ,
Dupilumab (Dupilumab) 💬
[2] IL17A,
IL4R 💬
[11] Alcoholic liver disease, Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬[1] 160 💬